Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 5.57
- Piotroski Score 7.00
- Grade Buy
- Symbol (INCY)
- Company Incyte Corporation
- Price $75.95
- Changes Percentage (0.26%)
- Change $0.2
- Day Low $75.35
- Day High $75.97
- Year High $76.57
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naïve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/11/2025
- Fiscal Year End N/A
- Average Stock Price Target $80.50
- High Stock Price Target $200.00
- Low Stock Price Target $48.00
- Potential Upside/Downside N/A
- Consensus Rating Buy
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $3.30
- Trailing P/E Ratio 17.93
- Forward P/E Ratio 17.93
- P/E Growth 17.93
- Net Income $597.60 M
Income Statement
Quarterly
Annual
Latest News of INCY
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Oprah Winfrey Mourns Quincy Jones as 'the First Person I Ever Loved Unconditionally': 'My Beloved Q'
Oprah Winfrey pays tribute to Quincy Jones, crediting him with discovering her for her role in "The Color Purple." She describes him as a person filled with love and light, whose legacy will be his im...
By PEOPLE.com | 16 hours ago -
Justin Timberlake Pays Tribute to Late 'Mentor' Quincy Jones: 'A Once in a Lifetime Artist'
Justin Timberlake paid tribute to the late Quincy Jones on Instagram, calling him a once-in-a-lifetime artist and mentor. Timberlake expressed gratitude for Jones' guidance and influence on his music ...
By PEOPLE.com | 16 hours ago -
12 Heartwarming Photos of Quincy Jones with His Kids
Quincy Jones, a legendary producer, achieved numerous accolades in his career, including collaborating with Michael Jackson on the iconic Thriller album. Despite his success, he always cherished his s...
By PEOPLE.com | 17 hours ago
